Role of sex hormones in the sexually dimorphic expression of KCC2 in rat substantia nigra.
KCC2 is a neuronal-specific potassium chloride cotransporter. The level of KCC2 expression is a factor determining whether GABA(A) receptor agonists depolarize or hyperpolarize neurons. Substantia nigra reticulata (SNR) neurons of male postnatal day 15 (PN15) rats have low KCC2 mRNA expression and respond to GABA(A) receptor activation with depolarization and activation of calcium-regulated gene expression. Female PN15 SNR neurons have high KCC2 mRNA expression and GABA(A) receptor agonists cannot activate calcium-dependent signaling processes. We investigate whether sex hormones regulate KCC2 mRNA expression in PN15 rat SNR. Using in situ hybridization, we studied the effects of acute (4 h) or prolonged (52 h) subcutaneous (s.c.) administration of testosterone (100 microg), dihydrotestosterone (180 microg) or 17beta-estradiol benzoate (5 microg) on KCC2 mRNA expression in male and female PN15 rat SNR. Different doses of estradiol (1 and 10 microg s.c., 4 h) were also acutely administered in female PN15 rats. Controls received oil injections. Separate groups of PN15 male rats were pretreated with antagonists of L-type voltage-sensitive calcium channels (L-VSCCs) [nifedipine, 100 mg/kg s.c.] or GABA(A) receptors [bicuculline, 2 mg/kg intraperitoneally (i.p.)] or their vehicles, 30 min before estradiol (5 microg s.c., 4 h). Testosterone and dihydrotestosterone upregulated KCC2 mRNA in both sexes. Estradiol downregulated KCC2 mRNA in males but not in females. Both acute and prolonged hormonal administration had similar effects. In male PN15 SNR, nifedipine and bicuculline decreased KCC2 mRNA acutely and prevented further downregulation of KCC2 mRNA by estradiol. Estradiol therefore downregulates KCC2 mRNA in male PN15 SNR, by interacting with the GABA(A) receptor and L-VSCC signaling pathway.
Galanopoulou
Aristea S
AS
Department of Neurology, Albert Einstein College of Medicine, Bronx, NY 10461, USA. agalan@aecom.yu.edu
Moshé
Solomon L
SL
D000818:Animals; D002121:Calcium Channel Blockers / Q000494:pharmacology; D020746:Calcium Channels, L-Type / Q000187:drug effects / Q000378:metabolism; D013196:Dihydrotestosterone / Q000494:pharmacology; D004958:Estradiol / Q000031:analogs & derivatives* / Q000494:pharmacology; D005260:Female; D018756:GABA Antagonists / Q000494:pharmacology; D012739:Gonadal Steroid Hormones / Q000494:pharmacology*; D017403:In Situ Hybridization; D008297:Male; D012333:RNA, Messenger / Q000032:analysis; D051381:Rats; D017207:Rats, Sprague-Dawley; D011963:Receptors, GABA-A / Q000187:drug effects / Q000378:metabolism; D012727:Sex Characteristics; D013378:Substantia Nigra / Q000502:physiology*; D027981:Symporters / Q000096:biosynthesis* / Q000187:drug effects; D013739:Testosterone / Q000494:pharmacology; D013997:Time Factors; D000096922:K Cl- Cotransporters
D002121:Calcium Channel Blockers; D020746:Calcium Channels, L-Type; D013196:Dihydrotestosterone; D004958:Estradiol; D018756:GABA Antagonists; D012739:Gonadal Steroid Hormones; D012333:RNA, Messenger; D011963:Receptors, GABA-A; D027981:Symporters; D013739:Testosterone; D000096922:K Cl- Cotransporters; C074283:estradiol 3-benzoate